Development of biomarkers for Alzheimer’s disease is critically important to advancing innovative payment models for treatments as well as care models for patients with the disease, according to Eli Lilly & Co.’s Phyllis Ferrell, head of external engagement for Alzheimers and neurodegeneration.
But “biomarkers are an objective way of measuring response to therapy that we don’t have today,” Ferrell pointed out during...







